Email  |  BV_FTP  |  OA

Hotline:+86 27 8798 8585  CN   |   EN

CN   |   EN

Current location:Home >> 首页焦点图

JOINN and BravoBio officially signed a Strategic Cooperation Agreement

Author:博沃管理员    Release time:2022-03-17 09:48:30

March 16, 2022 — JOINN Laboratories (China) Co., Ltd. (“JOINN Laboratories”), Beijing JOINN Biologics Co., Ltd. (“JOINN Biologics”), JOINN Clinical (Beijing) Co., Ltd. (“JOINN Clinical”), and Shanghai BravoBio Co., Ltd (“BravoBio”) today announced that the four parties have officially signed a Strategic Cooperation Agreement, becoming cooperative partners in vaccine R&D, evaluation and clinical research.

BravoBio is expecting to utilize JOINN’s integrated platforms and broad experience under this partnership, mobilize key resources from both JOINN and BravoBio, to expedite the development of vaccine candidates and move the vaccine pipelines into clinical stage in the fastest time possible.

Under the Agreement, JOINN will leverage its extensive experience in clinical research to support the development, evaluation and IND application for BravoBio’s multiple innovative vaccine candidates. BravoBio will utilize JOINN’s one-stop services from vaccine development, commercial manufacturing and clinical research, to achieve the seamless progression from vaccine R&D up to clinical stage.

About BravoBio

Shanghai BravoBio Co., Ltd (BravoBio) was established in Zhangjiang Hi-Tech Park in Shanghai in March 2011 and moved to North Shanghai Biopharma Park in October 2021. Its subsidiary company, BravoVax, is a “state level high-tech enterprise” and a council member of China Association of Vaccines (CAV). It was awarded as “China Rising Star” by Deloitte in 2020, becoming the only vaccine company to win this award. The company boasts a number of advanced technology platforms, including gene editing / construction / cloning / detection, large-scale bacterial / cell / virus culture, preparation of bioactive substances (polysaccharide, protein, virus, etc.), conjugation of polysaccharide and protein, novel adjuvant, new process and analytical assays, etc. to meet the needs of developing innovative biologics, especially vaccines. BravoBio has held the mission to improve the quality of people’s lives, aiming for a healthier and happier future.

About JOINN Laboratories

Founded in 1995, JOINN Laboratories (China) Co., Ltd. (JOINN Laboratories, Stock Code: 603127.SSE/6127.HK) is dedicated to providing drug R&D CRO outsourcing services with over 2000 professionals. Headquartered in Beijing, JOINN has subsidiaries in Beijing, Suzhou, Shanghai, Chongqing, Wuzhou and Guangzhou in China, and Richmond (CA) and Worcester (MA) in the United States. JOINN has built a thorough quality management system complied with international standards: CNAS/ILAC-MRA certification, NMPA, US FDA, OECD, Japan PMDA and Korean MFDS GLP certification and international AAALAC accreditation. JOINN can provide customized services tailored to the client’s specific needs for non-clinical safety assessments, clinical trials, registrations, and pharmacovigilance which cover the entire spectrum from development to final drug registration. JOINN also provides services in animal feed and veterinary medicine evaluation, pesticide evaluation, medical device evaluations, and more.

About JOINN Clinical

JOINN Clinical is a wholly-owned subsidiary of JOINN Laboratories. The company focuses on early phase clinical research (generic BE/clinical phase I & PK etc.), and has established a quality management system that conforms to international standards. 

JOINN Clinical supports sponsors from clinical study design to trial registration, clinical operation, monitoring, data management, statistics, and pharmacovigilance among other services. We aim to create a seamless transition from pre-clinical to clinical research for our sponsors. 

JOINN Clinical manages abundant hospital resources across multiple therapeutic areas, including oncology, metabolic, cardiovascular, respiratory, ophthalmic, and rare diseases, etc., and have carried out close cooperation with all mainstream hospitals.

JOINN Clinical's hospital base business has already built Phase I wards in cooperation with 3 hospitals, with a total of 200 beds. The centers have an international SOPs and quality management systems. The centers are adequately staffed and are experienced in advanced clinical trial management.

About JOINN Biologics

JOINN Biologics, founded in 2018, is a full-service premier Contract Development & Manufacturing Organization which provides clients with quality, value and speed to market from DNA to Drug Product.

The Group has a core team formed by scientists and engineers, with enriched industry experience and a broad spectrum of both Chinese and foreign laws and regulations about new drug. One of the sites, located in San Francisco Bay Area of USA, has capabilities of 1 x 200L, 2 x 500L, and 1x1,000L FDA GMP single-use/disposable bioreactors. Another site, located in Beijing BDA of China, has capabilities of 15 x 2,000L, multiple 500L and 200L Drug Substance (DS) single-use/disposable bioreactors, along with in-house supporting functions such as PD, R&D and Quality testing labs. The Group is building facilities based on Chinese, United States, European Union, WHO, and various international cGMP requirements. The facilities will be equipped with up to 100,000L Drug Substance (DS) production lines and a various of high-end freeze-dried powder injection, water injection, and pre-filled needle preparation production lines. In the meantime, the Group has multiple reactors from 50L to 5,000L, which can satisfy clinical and commercial batch API production needs under complex conditions.

Relying on the R&D and production facilities in China and the United States, the Group is able to provide global innovative drug R&D institutions with one-stop solutions in terms of development assessment, upstream and downstream process development, quality research, CMC development and commercial production.